Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): An open trial

Journal of Rheumatology

Volumn 27, Issue 3, 2000, Pages 723-726

  Dekker Saeys, Betty J ^a   Dijkmans, Ben A C ^a,b   Tytgat, Guido N J ^c  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

5 aminosalicylic acid; Spondyloarthropathy

Indexed keywords

MESALAZINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; RETREATMENT; SPONDYLITIS; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0034061693     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Fraser SM, Sturrock RD. Evaluation of sulphasalazine in ankylosing spondylitis - an interventional study. Br J Rheumatol 1990;29:37-9.
2. Weinblatt ME, Reda DJ, Henderson WG, et al. Sulfalazine treatment for rheumatoid arthritis: a meta-analysis of 17 randomized trials [abstract]. Arthritis Rheum 1997;40 Suppl 9:S51.
3. Taggert AJ, Neumann VC, Hill J, Astbury C, Le-Gallez P, Dixon JS. 5 Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? Drugs 1986;32 Suppl 1:27-34.
4. Neumann VC, Taggert AJ, Le-Gallez P, Astbury C, Hill J, Bird HA. A study to determine the active moiety of sulfasalazine in rheumatoid arthritis. J Rheumatol 1986;13:285-7.
5. Worth WD, Muller W. Die Wirkung der 5-Aminosalicylsaure als Bestandteil des Sulphasalazins in der Behandlung der chronischen Polyarthritis [Action of 5-ASA as ingredient in sulfasalazine in the treatment of chronic polyarthritis]. Z Rheumatol 1986;45:79-82.
6. Imai F, Suzuki T, Ishibashi T, Tanaka M, Akiyama Y, Dohi Y. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J Rheumatol 1994;21:612-5.
7. Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-9.
8. Dougados M, Maetzel A, Mijiyawa M, Amor B. Evaluation of sulphasalazine in the treatment of spondylarthropathies. Ann Rheum Dis 1992;51:955-8.
9. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
10. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004-12.
11. Maki-Ikola O, Nissila M, Lehtinen K, Leirisalo-Repo M, Granfors K. IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the serum of patients with peripheral and axial types of ankylosing spondylitis. Ann Rheum Dis 1995;54:631-5.
12. Maki-Ikola O, Nissila M, Lehtinen K, Leirisalo-Repo M, Toivanen P, Granfors K. Antibodies to Klebsiella pneumoniae, Escherichia Coli and Proteus mirabili in the sera of patients with axial and peripheral form of ankylosing spondylitis. Br J Rheumatol 1995;34:413-7.
13. Nissila M, Lahesmaa R, Leirisalo-Repo M, Lehtinen K, Toivanen P, Granfors K. Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in ankylosing spondylitis; effects of sulfasalazine treatment. J Rheumatol 1994;21:2082-7.
14. Meuwissen SGM, Dekker-Saeys BJ, Agenant D, Tytgat GNJ. Ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis 1978;37:30-2.
15. Dekker-Saeys BJ, Meuwissen SGM, Van den Berg-Loonen FM, De Haas WHD, Meijers KAF, Tytgat GNJ. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis 1978;37:36-41.
16. Mielants H, Veys EM, De Vos M, et al. The evolution of spondylarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995;22:2266-72.
17. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
18. Mielants H, Veys EM, Cuvelier C, de Vos M. Course and gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64.
19. Laasila K, Leirsalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol 1994;23:338-40.
20. Singleton JW, Hanauer SB, Gitnick GL, et al, and the Pentasa Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993;104:1293-301.
21. Hanauer SB, Schwaryz J, Robinson MG, et al, and the Pentasa Study Group. Mesalamine capsules for the treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterology 1993;88:1188-97.
22. Becx MCJM, Vollaard EJ. Oude of nieuwe geneesmiddelen bij inflammatoire darmziekte? [Old or new drugs in inflammatory bowel disease?]. Geneesmiddelenbulletin 1992;26:1-5.
23. Bennet PH, Burch TA. New York Symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 1967;17:453-8.
24. Van der Heijde D, Bellamy N, Cahn A, Dougados M, Khan MA Van der Linden S. Preliminary care sets for endpoints in ankylosing spondylitis. J Rheumatol 1997;24:225-9.
25. Van der Heijde D, Calin A, Dougados M, Khan MA, Van der Linden S, Bellamy N. Selection of specific instruments for each domain in core set for DC-ART, SM-ARD, physical therapy and clinical record keeping in ankylosing spondylitis. Progress report of ASAS working group. J Rheumatol 1999;26:951-4.
26. Meuwissen SGM, Crusius JBA, Pena AS, Dekker-Saeys AJ, Dijkmans BAC. Spondylarthropathy and idiopathic inflammatory bowel diseases. Inflamm Bowel Dis 1997;3:25-37.
27. Feltelius N, Hvatum M, Brandtzaeg P, Knutson L, Hallgren R. Increased jejunal secretory IgA and IgM in ankylosing spondylitis. J Rheumatol 1994;21:2076-81.
28. Taggert A, Gardiner Ph, McEvoy F, Hopkins R, Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum 1996;39:1400-5.
29. Chapman CM, Zwillich SH. Olsalazine in ankylosing spondylitis; a pilot study. J Rheumatol 1994;21:1699-701.
30. Thomson GTD, McKibbon C, Inman RD. Mesalamine therapy in Reiter's syndrome. Case report. J Rheumatol 1994;21:570-1.
31. Hollander D. Crohn's disease - a permeability disorder of the tight junction? Gut 1988;29:1621-4.